Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients at Assiut University Hospital

ConditionNAFLD - Nonalcoholic Fatty Liver Disease

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-75

SponsorAssiut University

About this trial

Aim of the study :-

1. to estimate prevalence of non alcoholic fatty liver disease and liver fibrosis among Systemic lupus erythematosus patients 2. to determine risk factors in SLE patients contributing to NAFLD and liver fibrosis

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients aged 18 years old ,Both sex male and female, diagnosed with SLE

Disqualifiers

Age below 18 years old

patients with hepatitis b virus (HBV), hepatitis c virus (HCV) or cirrhosis

malignancy, cardiac disease,

patients on dialysis.

Trial population

Adult patients aged 18 years old ,Both sex male and female, diagnosed with SLE

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

Fibroscan
Device
Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

estimation of prevalence of non alcoholic fatty liver disease and liver fibrosis among Systemic lupus erythematosus patients

We will divide lupus patients into 3 groups group number 1 who are SLE patient in activity and not taking treatment,group number 2 who are SLE patients in activity and taking treatment and controlled,group number 3 who are SLE patients in activity and taking treatment but not controlled our outcome is to estimate prevalence of NAFLD in each group .

Time frame

baseline

Secondary outcomes

determinate risk factors in SLE patients contributing to NAFLD and liver fibrosis

We will determine the risk factor in SLE patients we take and determine the risk factors in patients detected as having NAFLD and determine the risk factors may contributed to develop NAFLD

Time frame

baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: